Impact of a pharmacist-driven azithromycin de-escalation initiative for community-acquired pneumonia-Reference-Cited by-同舟云学术

Impact of a pharmacist-driven azithromycin de-escalation initiative for community-acquired pneumonia

Published:2020-09-21 Issue: Volume: Page:
ISSN:2574-9870
Container-title:Journal of the American College of Clinical Pharmacy
language:en
Short-container-title:J Am Coll Clin Pharm

Author:

Shakeraneh Pegah¹,Steele Jeffrey M.¹²,Seabury Robert W.¹²,Thomas Stephen J.²,Paolino Kristopher M.²,Miller Christopher D.¹²,Probst Luke A.¹²,Kufel Wesley D.¹²³^ORCID

Affiliation:

1. State University of New York Upstate University Hospital; Syracuse New York USA

2. State University of New York Upstate Medical University; Syracuse New York USA

3. Binghamton University School of Pharmacy and Pharmaceutical Sciences; Binghamton New York USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jac5.1325/fullpdf

Reference17 articles.

1. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality;Ramirez;Clin Infect Dis,2017

2. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America;Metlay;Am J Respir Crit Care Med,2019

3. Systematic review, meta-analysis, and network meta-analysis of the cardiovascular safety of macrolides;Gorelik;Antimicrob Agents Chemother,2018

4. Prevalence of atypical pathogens in patients with cough and community-acquired pneumonia: a meta-analysis;Marchello;Ann Fam Med,2016

5. Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective;Gramegna;BMC Infect Dis,2018